OUTSOURCED PHARMA CAPACITY UPDATE LARGE MOLECULE VIDEOS

22:58 3PBIOVIAN Large Mol October 2025
OPCU October 2025: Large Molecule

Advance your biotherapeutic with a trusted global CDMO partner offering end-to-end development and manufacturing, supported by state-of-the-art facilities and a commitment to your success.

15:25 nanoform large mol october 2025
Nanoform Capacity Update October 2025: Large Molecule

Sergie Letser, Deputy CCO, presents an overview of Nanoform’s novel large molecule nanoforming technology capabilities and current capacity.

19:24 Cytovance Large Mol October 2025
Cytovance Biologics Capacity Update October 2025: Large Molecule

Partner with a U.S.-based, trusted CDMO large enough to support every stage of your program, yet agile enough to deliver the dedicated care your project deserves.

23:34 Avid Bioservices Capacity Update October 2025 Large Molecule
From Concept To Market: Mammalian Protein Development And Manufacturing

With proven expertise in process development, optimization, and CGMP manufacturing, Avid offers end-to-end CDMO solutions backed by flexible capacity designed to scale with program needs.

18:54 AGC Large Mol OPCU October
AGC Biologics Capacity Update October 2025: Large Molecule

Michael Brotz provides an in-depth look at our Seattle site and the unique capabilities of the facility, including its single-use and stainless-steel capacity, new manufacturing lines, and more.

21:39 Samsung Large Mol October 2025
Samsung Biologics Capacity Update October 2025: Large Molecule

Accelerate your cancer therapy development with patient-derived organoids — high-fidelity models that enhance translational confidence, streamline discovery, and bring promising treatments to the clinic faster.

12:38 Novartis Large Mol October 2025
Novartis Contract Manufacturing Capacity Update October 2025: Large Molecule

Gain insight into our global manufacturing network, including information about the capabilities of each mammalian and microbial site within the network.

21:55 Northway Large Mol October 2025
Northway Biotech Capacity Update October 2025: Large Molecule

André Markmann, VP of Business Development, shares insights drawn from over 20 years of experience, more than 185 successful projects, and fully integrated microbial and mammalian facilities in Waltham, Massachusetts, and Vilnius, Lithuania.

16:41 Millipore Large Mol October 2025
MilliporeSigma Capacity Update October 2025: Large Molecule

Our global facilities are built to guide you when you’re ready to scale; and power your mRNA journey from discovery to global commercialization.

21:27 KBI Large Mol October 2025
KBI Biopharma Capacity Update October 2025: Large Molecule

Accelerate your biopharmaceutical program with a flexible, global manufacturing partner that minimizes risk, shortens timelines, and empowers seamless scaling from clinical to commercial production.

 

21:51 Boehringer Large Mol October 2025
Boehringer Ingelheim Biopharmaceuticals GmbH Capacity Update October 2025: Large Molecule

This session provides a comprehensive overview of our biopharmaceutical contract manufacturing services for mammalian cell culture and microbial technologies.

19:18 Abzena Large Mol October 2025
Abzena Capacity Update October 2025: Large Molecule

Accelerate your therapeutic antibody and complex protein development with advanced mammalian cell line platforms that move from DNA to RCB in just 10 weeks.

18:17 OP Capacity Update
Resilience Capacity Update July 2025: Large Molecule Drug Substance

Hear from Evan Pasenello, Head of Commercial Services, about how Resilience can support large molecule programs from early phase through clinical and commercial manufacturing.

21:54 OP Capacity Update
Novartis Contract Manufacturing Capacity Update July 2025: Large Molecule Drug Substance

Review biologics CDMO solutions and capacity offered by Novartis Contract Manufacturing. We discuss our capabilities in mammalian cell culture manufacturing and microbial fermentation.

22:07 OP Capacity Update
Providing Development And Supply Of Life-Changing Medicines

Review the strategic application of extensive expertise in microbial systems to meet the increasing demand for novel biologics. Cutting-edge capabilities ensure streamlined development and manufacturing processes.

20:03 OP Capacity Update
Cytovance Biologics Capacity Update July 2025: Large Molecule Drug Substance

Thomas Kohl, Director of Business Development, shares the company’s microbial and mammalian capabilities and their available capacity. Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike.

14:03 OP Capacity Update
Aragen Capacity Update July 2025: Large Molecule Drug Substance

Aragen’s newly built cutting-edge biologics manufacturing facility launches with GMP capabilities from 50L to 2000L—scaling to 5000L soon—with a DP filling line and ADC conjugation suite set to redefine bioproduction in India.

11:48 Northway Biotech April OPCU Large Mol
Northway Biotech Capacity Update April 2025: Large Molecule Development

Detra Glinatsis, Vice President of Business Development, presents the advanced capabilities, strategic growth, and expanding capacity of Northway Biotech, a global biologics CDMO.

21:59 Abzena April OPCU Large Mol
Abzena Capacity Update April 2025: Large Molecule Development

See first-hand how AbZelectPRO™, an evolved approach to cell line development, can simplify selection, enhance stability, and de-risk your program for faster regulatory approval.

22:07 Curia April OPCU Large Mol
Curia Capacity Update April 2025: Large Molecule Development

Site head Bill Hermans showcases our facility's specialized capabilities in Hopkinton, Massachusetts, and shares how our team serves as a true scientific partner to clients.

20:07 Cytovance April OPCU Large Mol
Cytovance Biologics Capacity Update April 2025: Large Molecule Development

Speed up your program with end-to-end microbial and mammalian biologics development and manufacturing expertise — spanning everything from biosimilars to vaccines.

18:25 Novartis April OPCU Large Mol
Novartis Capacity Update April 2025: Large Molecule Development

Experience a global network of expertise and proven manufacturing capabilities that can help accelerate your clinical and commercial drug substance programs.

17:57 Samsung April OPCU Large Mol
Samsung Biologics Capacity Update April 2025: Large Molecule Development

Leveraging advanced technology, expertise, and flexible capacity, clients can reduce development time and costs while ensuring a smooth transition from clinical to commercial manufacturing.

18:41 Boehringer April OPCU Large Mol
Boehringer Ingelheim Capacity Update April 2025: Large Molecule Development

Explore how world-class contract manufacturing expertise and global capabilities can help accelerate your biologic from development to commercial success.

20:51 Catalent April OPCU Large Mol
Leveraging Advanced Technology And Proven Expertise

By leveraging our proprietary non-viral gene insertion technology, GPEx® Lightning ensures rapid development timelines and high-yield production, making it an ideal solution for complex biologics.

24:39 FUJI April OPCU Large Mol
FUJIFILM Diosynth Biotechnologies Capacity Update April 2025: Large Molecule Development

Associate Director kojoX and Technology Development, Rasmus Petersen, presents a high-level overview of FDB’s capabilities, its global facilities network, and capacity updates for BIOLOGICS.

16:35 northway jan opcu large molecule
Northway Biotech Capacity Update January 2025: Large Molecule Development

Over the past 20 years, we have completed more than 175 successful projects around the globe, showcasing our commitment to quality and customer satisfaction.

20:21 mabion jan opcu large molecule
Mabion Capacity Update January 2025: Large Molecule Development

Go on a virtual tour of our GMP-certified facility, where we uphold our expanded capabilities for large molecule development to the highest standards for clinical and commercial manufacturing.

21:08 kbi jan opcu large molecule
KBI Biopharma Capacity Update January 2025: Large Molecule Development

Follow along as Derek Ryan, Sr. Director of Analytical Development, showcases our high-throughput technology and digital tools for process understanding and optimizing decision-making.

23:02 cytovance jan opcu large molecule
Cytovance Biologics Capacity Update January 2025: Large Molecule Development

Join Rose Rhomberg, Senior Business Development Director, as she showcases Cytovance’s microbial and mammalian capabilities, along with our available manufacturing capacity.

18:10 catalent opcu large jan
Catalent Capacity Update January 2025: Large Molecule Development

Learn how our expertise and advanced capabilities provide customized analytical solutions that ensure quality, precision, and regulatory compliance for your biotherapeutics.

19:17 Cytovance LMD
Cytovance Capacity Update July 2024: Large Molecule Development

Centrally located in the United States, with a decades-long history in biologics development and manufacturing, Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike.

Agenda & Presenter Details

Visit our registration pages to see the current agenda and our list of presenting sponsors.

How can we help?

Are you a supplier looking to present at our next event?

Become A Presenter